Algernon Health CEO Christopher Moreau joined Steve Darling from Proactive to announce the company will open its inaugural brain PET scanning clinic at the HCA Florida University Medical Office Building, located on the campus of HCA Florida University Hospital. The clinic will be operated by Algernon USA LLC, a wholly owned subsidiary, which has signed a five-year lease with an option to renew for an additional five years. The company also plans to expand with multiple clinics across the United States as part of a broader rollout strategy. Moreau highlighted that the facility will be the first of its kind in the U.S. dedicated to brain-specific PET imaging. The clinic will focus on early detection and diagnosis of neurological conditions including Alzheimer’s disease, dementia, epilepsy, neuro-oncology indications, and movement disorders such as Parkinson’s disease. The site will feature the CareMiBrain system, an FDA-cleared standalone PET scanner designed specifically for brain imaging. Unlike traditional systems, it does not require an integrated CT component, enabling high-quality imaging while reducing patient radiation exposure by approximately 25%. Importantly, brain PET scans used for beta-amyloid plaque detection are covered by Medicare, Medicaid, and private insurance for patients aged 65 and older. This is particularly relevant given the emergence of new Alzheimer’s treatments such as Leqembi and Kisunla, both of which require confirmation of amyloid plaque presence—via PET scan or spinal tap—before patients can begin therapy. These developments are helping drive rapid growth in the Alzheimer’s diagnostics and treatment market, creating a significant opportunity for specialized brain imaging services. Algernon plans to work closely with neurologists, geriatricians, and primary care providers to build referral networks, while also targeting the 50+ population directly to raise awareness around early detection. The company emphasized that beta-amyloid plaques can develop 15 to 20 years before symptoms appear, reinforcing the value of early screening through cognitive testing, blood biomarkers, and advanced imaging. #proactiveinvestors #algernonpharmaceuticalsinc #cse #agn #otcqb #agnpf #alzheimerdisease #demetia #AlgernonHealth #BrainHealth #MedicalImaging #HealthcareInnovation #PETScan #Neurodegeneration #Biotech #EarlyDetection #ChristopherMoreau #BrainPET #MedicalImaging #HealthcareInnovation #Alzheimers #Dementia #Parkinsons #Neurology #PETScan #EarlyDetection #HealthTech #MedTech #CareMiBrain #Diagnostics #AgingPopulation #Healthcare #Biotech #Innovation #USHealthcare